Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lung Neoplasms 25Prostatic Neoplasms 23Carcinoma, Non-Small-Cell Lung 15Multiple Myeloma 14Sarcoma 12Leukemia, Myeloid, Acute 12Breast Neoplasms 12Lymphoma, Non-Hodgkin 10Glioma 10Wilms Tumor 9Colorectal Neoplasms 9Carcinoma, Hepatocellular 9Rectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Pancreatic Neoplasms 8Ovarian Neoplasms 8Osteosarcoma 8Neuroblastoma 8Neoplasm Metastasis 8Myelodysplastic Syndromes 8Rhabdomyosarcoma 7Rhabdoid Tumor 7Melanoma 7Medulloblastoma 7Hepatoblastoma 7Neuroectodermal Tumors, Primitive, Peripheral 6Mouth Neoplasms 6Lymphoma 6Histiocytosis, Langerhans-Cell 6Head and Neck Neoplasms 6

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced NUT Carcinoma × X-Rays × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡